Fig. 6.
Two muscarinic-receptor-modulating compounds identified in pilot screening: (A) ipratropium bromide—a muscarinic receptor antagonist used to treat bronchial spasms, and (B) edrophonium chloride—an acetylcholinesterase inhibitor shown to also interact with the human M1 muscarinic receptor used to treat myasthenia gravis. Maximal percent inhibition shown relative to DMSO controls.